Personalis to Present at the Stifel 2024 Healthcare Conference
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105986994/en/
Investors:
Caroline Corner
[email protected]
415-202-5678
Media:
[email protected]
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike
- App Development Costs Drop From $200,000 to Near $50,000 as Chop Dawg Pairs AI-Accelerated Engineering With 18 Years of Discipline
- Official Trump Price Prediction: Could TRUMP Reach $100 as Trump’s Crypto Push Sends AlphaPepe Risk Appetite Higher?
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Stifel, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share